A Borophosphate Glass Doped with Cobalt Oxide Improves Skeletal Muscle Structure and Function in Myopathic Mice
Source abstract
Abstract
Skeletal muscle myopathy remains a significant cause of disability with limited treatment strategies. Advancements in tissue engineering have led to the development of borophosphate bioactive glasses (BPBGs) capable of enhancing skeletal muscle structure and function. Using a mouse model of severe myopathy (D2.mdx), we investigated muscle force, regeneration, angiogenesis and inflammation at 14, 70 and 140 days post-treatment (dpt). Tibialis anterior (TA) muscles of D2.mdx mice that received a single injection of cobalt oxide-doped BPBG (CoO-TRIM) particles exhibit greater active force, myofiber size, and regeneration through 70 dpt compared to control D2.mdx mice injected with Saline. Vascular endothelial growth factor (VEGF) was elevated up to 70 dpt in D2.mdx CoO-TRIM mice followed by increased muscle vascularity. As a marker of inflammation, interleukin (IL)-6 increased in D2.mdx CoO-TRIM mice compared to D2.mdx Saline controls at 14 dpt, with no differences at 70 or 140 dpt. No differences were observed in outcome measures between wild-type (WT) CoO-TRIM mice and WT Saline controls. We report that CoO-TRIM can stimulate VEGF production and promote restoration of muscle structure and function when inflammation is present. Local injection of an inorganic biomaterial alone can benefit myopathic skeletal muscle.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Muscle Physiology and Disorders · Bone Tissue Engineering Materials · Heterotopic Ossification and Related Conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Kinesiology and Sport Management, Texas A&M University, College Station, TX 77845, USA
Department of Materials Science & Engineering, Missouri University of Science & Technology, Rolla, MO 65409, USA
Department of Pediatric Neurology, The Children’s Hospital at Montefiore, Bronx, NY 10467, USA
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA
Dalton Cardiovascular Research Center, Columbia, MO 65211, USA
Department of Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA
Department of Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, MO 65201, USA
Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO 65211, USA
Funding
University of Missouri School of Medicine Coulter Biomedical Accelerator Grant · Missouri S&T Ignition Grant Initiative · TAMU Advancing Discovery to Marketplace Innovation Award · College of Education and Human Development at Texas A&M University · NIH LRP · NIH
References (100+)
Show source-provided references
1. Membrane injury and repair in the muscular dystrophies10.1177/1073858414558336 ↗
2. Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophy10.1111/j.1440-1681.2004.04026.x ↗
3. Langhans, C., Weber-Carstens, S., Schmidt, F., Hamati, J., Kny, M., Zhu, X., Wollersheim, T., Koch, S., Krebs, M., and Schulz, H. (2014). Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy. PLoS ONE, 9.10.1371/journal.pone.0092048 ↗
4. Duchenne muscular dystrophy10.1038/s41572-021-00248-3 ↗
5. The muscular dystrophies10.1016/S0140-6736(02)07815-7 ↗
6. Immune-mediated necrotizing myopathy10.1007/s11926-018-0732-6 ↗
7. D’Souza, D.M., Al-Sajee, D., and Hawke, T.J. (2013). Diabetic myopathy: Impact of diabetes mellitus on skeletal muscle progenitor cells. Front. Physiol., 4.10.3389/fphys.2013.00379 ↗
8. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease10.1177/1358836X0000500109 ↗
9. Percival, J.M., Anderson, K.N., Gregorevic, P., Chamberlain, J.S., and Froehner, S.C. (2008). Functional deficits in nNOSμ-deficient skeletal muscle: Myopathy in nNOS knockout mice. PLoS ONE, 3.10.1371/journal.pone.0003387 ↗
10. Muscle fiber dysfunction contributes to weakness in inclusion body myositis10.1016/j.nmd.2019.03.001 ↗
11. Bencze, M. (2022). Mechanisms of myofibre death in muscular dystrophies: The emergence of the regulated forms of necrosis in myology. Int. J. Mol. Sci., 24.10.3390/ijms24010362 ↗
12. Impaired functional and structural recovery after muscle injury in dystrophic mdx mice10.1016/S0960-8966(96)00422-1 ↗
13. The myopathy of peripheral arterial occlusive disease: Part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction10.1177/1538574407311106 ↗
14. The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type10.1177/1538574408315995 ↗
15. Distribution of capillaries in normal and diseased human skeletal muscle10.1002/mus.880090510 ↗
16. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition10.1002/(SICI)1097-4598(200001)23:1<106::AID-MUS14>3.0.CO;2-D ↗
17. Proteolysis in illness-associated skeletal muscle atrophy: From pathways to networks10.3109/10408363.2011.586171 ↗
18. Satellite cell depletion in degenerative skeletal muscle10.1023/A:1026127307457 ↗
19. Kodippili, K., and Rudnicki, M.A. (2023). Satellite cell contribution to disease pathology in Duchenne muscular dystrophy. Front. Physiol., 14.10.3389/fphys.2023.1180980 ↗
20. Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background10.1038/srep38371 ↗
21. Biomaterials10.1126/science.6246576 ↗
22. The story of Bioglass10.1007/s10856-006-0432-z ↗
23. Third-generation biomedical materials10.1126/science.1067404 ↗
24. Functionalizing biomaterials to promote neurovascular regeneration following skeletal muscle injury10.1152/ajpcell.00501.2020 ↗
25. Wu, Q., Mei, M.L., Wu, X., Shi, S., Xu, Y., Chu, C.H., and Chen, Y. (2020). Remineralising effect of 45S5 bioactive glass on artificial caries in dentine. BMC Oral Health, 20.10.1186/s12903-020-1038-4 ↗
26. Cannio, M., Bellucci, D., Roether, J.A., Boccaccini, D.N., and Cannillo, V. (2021). Bioactive glass applications: A literature review of human clinical trials. Materials, 14.10.3390/ma14185440 ↗
27. In vitro bioactive characteristics of borate-based glasses with controllable degradation behavior10.1111/j.1551-2916.2006.01358.x ↗
28. Conversion of melt-derived microfibrous borate (13-93B3) and silicate (45S5) bioactive glass in a simulated body fluid10.1007/s10856-012-4831-z ↗
29. Bioactive glass in tissue engineering10.1016/j.actbio.2011.03.016 ↗
30. Tackling bioactive glass excessive in vitro bioreactivity: Preconditioning approaches for cell culture tests10.1016/j.actbio.2018.05.019 ↗
31. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle10.1002/jbm.820070304 ↗
32. Twenty-first century challenges for biomaterials10.1098/rsif.2010.0151.focus ↗
33. A review on borate bioactive glasses (BBG): Effect of doping elements, degradation, and applications10.1039/D2TB02505A ↗
34. Boron-containing bioactive glasses in bone and soft tissue engineering10.1016/j.jeurceramsoc.2017.11.001 ↗
35. The angiogenic potential of pH-neutral borophosphate bioactive glasses10.1002/jbm.a.37553 ↗
36. Glass-activated regeneration of volumetric muscle loss10.1016/j.actbio.2019.12.007 ↗
37. Dissolution rates of borophosphate glasses in deionized water and in simulated body fluid
38. Bioactive glasses in wound healing: Hope or hype?10.1039/C7TB01221G ↗
39. Processing and characterization of novel borophosphate glasses and fibers for medical applications10.1016/j.jnoncrysol.2015.05.028 ↗
40. Bioactive glasses and electrospun composites that release cobalt to stimulate the HIF pathway for wound healing applications10.1186/s40824-020-00202-6 ↗
41. Solanki, A.K., Autefage, H., Rodriguez, A.R., Agarwal, S., Penide, J., Mahat, M., Whittaker, T., Nommeots-Nomm, A., Littmann, E., and Payne, D.J. (2023). Cobalt containing glass fibres and their synergistic effect on the HIF-1 pathway for wound healing applications. Front. Bioeng. Biotechnol., 11.10.3389/fbioe.2023.1125060 ↗
42. Cobalt-containing borate bioactive glass fibers for treatment of diabetic wound10.1007/s10856-023-06741-3 ↗
43. Accelerating full-thickness skin wound healing using Zinc and Cobalt doped-bioactive glass-coated eggshell membrane10.1016/j.jddst.2023.104273 ↗
44. Copper and cobalt doped bioactive glass-fish dermal collagen electrospun mat triggers key events of diabetic wound healing in full-thickness skin defect model10.1016/j.jmbbm.2022.105414 ↗
45. Exosomes derived from macrophages upon cobalt ion stimulation promote angiogenesis10.1016/j.colsurfb.2021.111742 ↗
46. Synthesis and characterization of hypoxia-mimicking bioactive glasses for skeletal regeneration10.1039/c0jm01111h ↗
47. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W310.1002/jbm.820240607 ↗
48. Chromatographic studies of the structures of amorphous phosphates: A review10.1016/S0022-3093(99)00644-4 ↗
49. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy10.1038/s41598-020-70987-y ↗
50. Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy10.1096/fj.201802488R ↗
51. Altered muscle niche contributes to myogenic deficit in the D2-mdx model of severe DMD10.1038/s41420-023-01503-0 ↗
52. Latent TGF-β-binding protein 4 modifies muscular dystrophy in mice10.1172/JCI39845 ↗
53. Of mice and measures: A project to improve how we advance Duchenne muscular dystrophy therapies to the clinic10.3233/JND-180324 ↗
54. Effect of genetic background on the dystrophic phenotype in mdx mice10.1093/hmg/ddv460 ↗
55. Genetic background affects properties of satellite cells and mdx phenotypes10.2353/ajpath.2010.090887 ↗
56. Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice10.1093/carcin/bgs213 ↗
57. Kendra, J.A., Hao, J., Harris, D.R., Blatt, R.L., Naman, A.G., Goble, S.D., Garcia, L.D., Brow, R.K., and Morton, A.B. (2025). Skeletal muscle regeneration is accelerated following injection of time release ion matrix in injured mice. bioRxiv.10.1101/2025.11.21.689759 ↗
58. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury10.1023/A:1014587918367 ↗
59. Evaluation of muscle function of the extensor digitorum longus muscle ex vivo and tibialis anterior muscle in situ in mice
60. Eaton, S.L., Roche, S.L., Hurtado, M.L., Oldknow, K.J., Farquharson, C., Gillingwater, T.H., and Wishart, T.M. (2013). Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS ONE, 8.10.1371/journal.pone.0072457 ↗
61. Baino, F., Montazerian, M., and Verné, E. (2023). Cobalt-doped bioactive glasses for biomedical applications: A review. Materials, 16.10.3390/ma16144994 ↗
62. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model10.1038/labinvest.3700328 ↗
63. Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α10.1074/jbc.M300463200 ↗
64. Cobalt, chromium and nickel affect hydroxyapatite crystal growth in vitro10.1016/j.actbio.2009.10.035 ↗
65. Surface immobilization mechanisms of cobalt ions on hydroxyapatite catalyst supports10.1016/j.cattod.2024.114621 ↗
66. Pyrophosphate: A key inhibitor of mineralization10.1016/j.coph.2016.03.003 ↗
67. Can biological calcification occur in the presence of pyrophosphate?10.1016/0003-9861(84)90356-4 ↗
68. Calpains are activated in necrotic fibers from mdx dystrophic mice10.1074/jbc.270.18.10909 ↗
69. Killing two angry birds with one stone: Autophagy activation by inhibiting calpains in neurodegenerative diseases and beyond10.1155/2019/4741252 ↗
70. How to interpret LC3 immunoblotting10.4161/auto.4600 ↗
71. Bioactive glass and silica particles for skeletal and cardiac muscle tissue regeneration10.1089/ten.teb.2023.0277 ↗
72. Involvement of endothelial PECAM-1/CD31 in angiogenesis
73. Schlüter, A., Weller, P., Kanaan, O., Nel, I., Heusgen, L., Höing, B., Haßkamp, P., Zander, S., Mandapathil, M., and Dominas, N. (2018). CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. BMC Cancer, 18.10.1186/s12885-018-4180-5 ↗
74. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies10.1177/1947601911423031 ↗
75. Role of vascular endothelial growth factor in the regulation of angiogenesis10.1046/j.1523-1755.1999.00610.x ↗
76. Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle10.1038/mt.2009.136 ↗
77. Endothelial cell signature in muscle stem cells validated by VEGFA-FLT1-AKT1 axis promoting survival of muscle stem cell10.7554/eLife.73592 ↗
78. VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice10.1096/fj.07-8459com ↗
79. VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy10.1016/j.omtm.2021.03.013 ↗
80. Mechanisms of muscle injury, repair, and regeneration10.1002/j.2040-4603.2011.tb00387.x ↗
81. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes10.1006/bbrc.1995.2590 ↗
82. Macrophages are key regulators of stem cells during skeletal muscle regeneration and diseases10.1155/2019/4761427 ↗
83. Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro10.1089/ten.2005.11.768 ↗
84. Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy10.1155/2012/691641 ↗
85. Borate bioactive glasses (BBG): Bone regeneration, wound healing applications, and future directions10.1021/acsabm.2c00384 ↗
86. Bioceramics10.1111/j.1151-2916.1998.tb02540.x ↗
87. Kinetics and mechanisms of the conversion of silicate (45S5), borate, and borosilicate glasses to hydroxyapatite in dilute phosphate solutions10.1007/s10856-006-9220-z ↗
88. The enhanced angiogenic responses to ionic dissolution products from a boron-incorporated calcium silicate coating10.1016/j.msec.2019.04.009 ↗
89. Simultaneous boron ion-channel/growth factor receptor activation for enhanced vascularization10.1002/adbi.201800220 ↗
90. Dose-dependent effect of boric acid on myogenic differentiation of human adipose-derived stem cells (hADSCs)10.1007/s12011-015-0253-3 ↗
91. Potential toxicity of bioactive borate glasses in-vitro and in-vivo
92. Evaluation of borate bioactive glass scaffolds as a controlled delivery system for copper ions in stimulating osteogenesis and angiogenesis in bone healing10.1039/C4TB01355G ↗
93. Hypoxia-mimicking mesoporous bioactive glass scaffolds with controllable cobalt ion release for bone tissue engineering10.1016/j.biomaterials.2011.11.042 ↗
94. Impact of transition metal ions on the structure and bioactivity of alkali-free bioactive glasses10.1016/j.jnoncrysol.2018.12.003 ↗
95. Effect of boron addition on the thermal, degradation, and cytocompatibility properties of phosphate-based glasses10.1155/2013/902427 ↗
96. In vitro dissolution of melt-derived 45S5 and sol-gel derived 58S bioactive glasses10.1002/jbm.10207 ↗
97. Dose-dependent behavior of bioactive glass dissolution10.1002/jbm.10053 ↗
98. TRIS buffer in simulated body fluid distorts the assessment of glass-ceramic scaffold bioactivity10.1016/j.actbio.2011.02.028 ↗
99. Bioactive Ceramics10.1111/j.1749-6632.1988.tb38500.x ↗
100. Calcium orthophosphates (CaPO4): Occurrence and properties10.1007/s40204-015-0045-z ↗